Drugs Containing Excipient (Inactive Ingredient) FORMALDEHYDE

« Back to Dashboard

Branded drugs containing FORMALDEHYDE excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Prestium Pharma Inc	ELIMITE	permethrin	40076-230	FORMALDEHYDE
Aurobindo Pharma Limited	ELIMITE	permethrin	59651-834	FORMALDEHYDE

Generic drugs containing FORMALDEHYDE excipient

Company	Ingredient	NDC	Excipient
Actavis Pharma Inc	permethrin	0472-0242	FORMALDEHYDE
Grifols USA LLC	tetanus and diphtheria toxoids adsorbed	13533-131	FORMALDEHYDE
MassBiologics	tetanus and diphtheria toxoids adsorbed	14362-0111	FORMALDEHYDE
Northstar Rx LLC	permethrin	16714-897	FORMALDEHYDE
Encube Ethicals Inc	permethrin cream 5% w/w	21922-021	FORMALDEHYDE
Prestium Pharma Inc	permethrin	40076-230	FORMALDEHYDE

Formaldehyde Pharmaceutical Excipient Market Dynamics and Financial Trajectory

Last updated: September 30, 2026

Formaldehyde is a regulated process chemical with limited direct use as a pharmaceutical excipient. Its pharmaceutical relevance is concentrated in vaccine inactivation, toxoid production, sterilization-related processes, and selected preservative applications. The broader formaldehyde market is valued in the multibillion-dollar range, but pharmaceutical demand represents a small and largely undisclosed share of industry revenue.

What is the pharmaceutical role of formaldehyde?

Formaldehyde is primarily used in pharmaceutical manufacturing as a processing or inactivation agent rather than as a conventional tablet or capsule excipient.

Use area	Pharmaceutical function	Commercial relevance
Vaccines	Inactivates viruses and detoxifies bacterial toxins	Highest pharmaceutical relevance
Toxoid vaccines	Converts toxins into immunologically active, non-toxic toxoids	Established use
Biological manufacturing	Chemical treatment of selected biological materials	Process-specific
Preservation	Antimicrobial activity in limited historical or specialized applications	Restricted and declining
Sterilization	Formaldehyde gas or solution in controlled environments	Limited by worker-safety rules
Finished-dose formulation	Direct formulation excipient	Uncommon

Formaldehyde is not a mainstream functional excipient comparable with lactose, microcrystalline cellulose, polysorbates, polyethylene glycol, or benzyl alcohol. In many pharmaceutical applications, any residual formaldehyde is treated as a process impurity requiring control rather than as an intended formulation component.

The chemical is commonly supplied as aqueous formalin, generally containing about 37% formaldehyde by weight with methanol or another stabilizer. Pharmaceutical users typically purchase controlled-quality solutions or prepare working concentrations within validated manufacturing systems.

How large is the global formaldehyde market?

Public market studies generally place the global formaldehyde market at approximately $5 billion to $7 billion in 2023-2024, depending on whether downstream formaldehyde derivatives are included. Forecast compound annual growth rates commonly fall in the 4% to 6% range through 2030. Pharmaceutical applications are not normally reported as a separate audited segment. (Grand View Research, 2024; MarketsandMarkets, 2024)

Global market indicators

Metric	Estimated range or status
Global formaldehyde market, 2023-2024	$5 billion-$7 billion
Expected market growth through 2030	Approximately 4%-6% CAGR
Dominant end use	Resins, adhesives, engineered wood and construction materials
Pharmaceutical share	Not separately disclosed; likely low single-digit percentage or less
Principal production regions	China, North America, Europe and the Middle East
Main feedstocks	Methanol and air
Product forms	Aqueous formaldehyde, paraformaldehyde and solid or stabilized derivatives

The pharmaceutical segment is economically small compared with phenolic resins, urea-formaldehyde resins, melamine-formaldehyde resins, polyoxymethylene and construction adhesives. Pharmaceutical demand is more sensitive to regulatory qualification and supply assurance than to absolute volume.

What is driving demand for pharmaceutical-grade formaldehyde?

Demand is linked to biologics manufacturing rather than conventional oral solid-dose production.

Vaccine and toxoid manufacturing

Formaldehyde remains relevant in the production of certain vaccines and toxoids because it can inactivate pathogens or detoxify bacterial toxins while preserving antigenic properties. The process must be validated for concentration, temperature, exposure time, mixing and residual removal.

The commercial implication is that demand is tied to:

• Vaccine production volumes
• Public-sector immunization programs
• Pandemic preparedness
• Contract manufacturing capacity
• Regulatory acceptance of the manufacturing process
• Availability of qualified formaldehyde suppliers

Vaccine manufacturers generally do not disclose formaldehyde consumption because it is a minor process input relative to antigen, adjuvant, fill-finish and cold-chain costs.

Sterilization and decontamination

Formaldehyde has historical use in fumigation and decontamination. Its use has declined where hydrogen peroxide vapor, chlorine dioxide, peracetic acid or other systems provide a more favorable occupational and regulatory profile.

Preservative applications

Direct use in finished pharmaceutical products is constrained by toxicity, sensitization and carcinogenicity concerns. Where a preservative is needed, manufacturers generally prefer alternatives with established pharmacopeial specifications and broader regulatory acceptance.

What is the financial trajectory of the formaldehyde market?

The broader market is likely to experience moderate nominal growth, but pharmaceutical-grade demand should grow more slowly in volume and faster in value because of compliance costs.

Revenue outlook

Period	Broad market trajectory	Pharmaceutical-grade trajectory
2020-2021	Disruption from pandemic logistics, uneven industrial demand	Vaccine-related demand supported activity
2022-2023	Recovery in industrial production, high energy and methanol costs	Stable to increasing demand from biologics manufacturing
2024-2026	Moderate growth with regional divergence	Low-volume growth, higher qualification and documentation costs
2027-2030	Approximately mid-single-digit market growth in many forecasts	Value growth likely exceeds volume growth

Formaldehyde pricing is driven primarily by methanol prices, natural gas and electricity costs, plant utilization, freight, environmental controls and local supply-demand conditions. Pharmaceutical buyers pay a premium for qualified packaging, traceability, impurity controls, validated manufacturing and change-control commitments. That premium does not necessarily create high margins because formaldehyde remains a hazardous commodity with significant compliance overhead.

Financial pressure points

The main margin risks are:

1. Methanol cost volatility.
2. Environmental-control capital expenditure.
3. Worker-protection requirements.
4. Hazardous-material transport costs.
5. Plant shutdowns caused by emissions violations.
6. Customer requalification after supplier or site changes.
7. Liability exposure from carcinogen classification.
8. Substitution by less hazardous process chemicals.

The financial profile therefore differs from that of specialty excipients. A qualified formaldehyde supplier can earn more from reliability and regulatory documentation than from molecular differentiation.

Which companies supply formaldehyde relevant to pharmaceutical manufacturing?

The global supply base is fragmented across large chemical companies, regional producers and specialized formaldehyde manufacturers.

Potentially relevant suppliers and producers include:

• BASF SE
• Hexion Inc.
• Prefere Resins Holding GmbH
• Georgia-Pacific Chemicals LLC
• Ercros S.A.
• Perstorp Holding AB
• Celanese Corporation
• Methanex Corporation, through methanol supply rather than formaldehyde production
• Regional producers in China, India, Southeast Asia and Latin America

The supplier set varies by country because formaldehyde is normally produced near methanol supply, resin plants or major industrial users. Pharmaceutical manufacturers often qualify a local or regional supplier rather than purchase from the largest global producer.

Supplier selection is based on:

• Assay and concentration control
• Methanol and other impurity limits
• Trace metals and nonvolatile residue
• Microbiological controls where applicable
• Packaging compatibility
• Certificate-of-analysis quality
• Change-notification procedures
• Site audit results
• Supply continuity and emergency allocation

What regulatory status applies to formaldehyde in pharmaceuticals?

Formaldehyde is subject to overlapping pharmaceutical, occupational, environmental and chemical-safety requirements.

FDA status

The FDA treats formaldehyde according to its intended use and residual presence. It is not generally recognized as a routine inactive ingredient for oral or injectable drug formulations. Where used in vaccine or biologic manufacturing, the manufacturer must demonstrate process control, product quality and acceptable residual levels through the applicable biologics application.

The FDA Inactive Ingredient Database is the relevant reference for approved inactive ingredients and route-specific precedents. A process use in manufacturing does not automatically establish formaldehyde as an approved finished-product excipient. (U.S. Food and Drug Administration, 2024)

Vaccine residuals

Some licensed vaccines contain residual formaldehyde from manufacturing. The residual quantity is controlled through product specifications and regulatory review. The acceptable level is product-specific rather than a universal commercial specification for every pharmaceutical application.

Occupational exposure

The U.S. Occupational Safety and Health Administration regulates formaldehyde exposure. OSHA’s formaldehyde standard includes an 8-hour permissible exposure limit of 0.75 parts per million and a short-term exposure limit of 2 parts per million over 15 minutes. (Occupational Safety and Health Administration, 2024)

International classification

The International Agency for Research on Cancer classifies formaldehyde as carcinogenic to humans. That classification increases compliance costs and encourages substitution where technically feasible. (International Agency for Research on Cancer, 2012)

The European Union also applies extensive controls under REACH and workplace chemical-safety rules. European manufacturers face pressure to minimize emissions, exposure and nonessential uses.

What patents protect pharmaceutical formaldehyde uses?

There is no commercially important composition-of-matter patent estate for formaldehyde itself. The compound is long established and cannot support new-molecule exclusivity.

Patent protection may instead cover:

• Specific vaccine inactivation conditions
• Toxoid detoxification processes
• Formaldehyde concentration and exposure-time combinations
• Stabilized formaldehyde formulations
• Low-residual vaccine manufacturing methods
• Sterilization systems
• Formaldehyde-generating solid compositions
• Combination decontamination systems
• Manufacturing equipment and emission-control methods

These patents generally protect a process, product composition or apparatus. They do not create broad exclusivity over pharmaceutical-grade formaldehyde.

Orange Book and Paragraph IV status

Formaldehyde has no meaningful Orange Book patent position as an active pharmaceutical ingredient. It is not a conventional FDA-approved small-molecule drug with listed composition patents, method-of-use patents or formulation patents.

As a result:

• There is no standard Orange Book exclusivity timeline.
• Paragraph IV litigation is generally not applicable.
• Generic-drug entry is not the main competitive issue.
• Patent risk arises at the customer process or finished biologic level.

A vaccine manufacturer may hold patents relating to antigen production or inactivation, but those rights do not normally block another company from buying formaldehyde as a commodity input.

How strong is the patent estate for formaldehyde?

The patent estate is weak for the chemical itself and potentially meaningful for application-specific processes.

Patent category	Strength for formaldehyde suppliers	Commercial effect
Composition of matter	None of practical significance	No molecule-level exclusivity
Pharmaceutical formulation	Limited	May protect specialized residual-control systems
Vaccine processing	Moderate to strong in narrow cases	Can protect customer manufacturing methods
Sterilization equipment	Moderate	Supports equipment and system differentiation
Emission-control technology	Moderate	Can create compliance and cost advantages
Supplier manufacturing process	Limited unless technically distinctive	Usually difficult to enforce against commodity supply

Patent expiration dates must be reviewed at the individual process or equipment level. There is no single formaldehyde patent expiration date that determines market entry.

What manufacturing and intellectual-property barriers affect supply?

The largest barriers are operational and regulatory, not patent-based.

Manufacturing barriers

Formaldehyde production is chemically straightforward but difficult to operate within modern environmental and occupational limits. Producers must manage:

• Methanol oxidation or dehydrogenation systems
• Flammable feedstocks
• Corrosive and toxic product handling
• Emissions of formaldehyde and volatile organic compounds
• Wastewater treatment
• Stabilizer management
• Hazardous-material storage and transport
• Continuous process monitoring

Pharmaceutical customers add qualification requirements. A supplier change can require comparability assessments, stability studies, process validation or regulatory notification.

Geographic coverage

China is a major global production center. North America and Europe retain significant capacity, particularly near resin, construction and chemical manufacturing clusters. Pharmaceutical users often maintain regional supply because formaldehyde is hazardous to transport and because supply interruptions can affect validated biological processes.

Geographic diversification is constrained by:

• Local emissions permits
• Feedstock availability
• Transport restrictions
• Site qualification
• Import documentation
• Regional chemical registration
• Customer-specific audits

How does formaldehyde compare with alternative inactivation and sterilization chemicals?

Chemical or technology	Relative advantage	Limitation compared with formaldehyde
Formaldehyde	Established vaccine and toxoid chemistry; low raw-material cost	Carcinogenicity, residual control and worker exposure
Beta-propiolactone	Used for selected viral inactivation	Higher process and handling requirements; hydrolysis behavior
Glutaraldehyde	Strong disinfectant and crosslinking activity	Toxicity and residual concerns
Hydrogen peroxide vapor	Lower persistent residue; effective room decontamination	Material compatibility and process validation
Peracetic acid	Broad antimicrobial activity	Corrosiveness and stability
Heat treatment	No chemical residual	May damage heat-sensitive biological products

Substitution is most likely in facility decontamination and sterilization. It is less straightforward in vaccine and toxoid manufacturing, where formaldehyde may be embedded in a validated process with established product comparability.

What generic launch risks exist for pharmaceutical formaldehyde?

Traditional generic launch risk is minimal because formaldehyde is not a branded drug with an Orange Book patent barrier. The main commercial risks are:

• A customer switching to another inactivation chemistry
• Loss of a qualified supplier status
• Regulatory rejection of a residual level
• Supply interruption
• Plant closure or emissions restriction
• Customer consolidation
• Replacement by lower-hazard alternatives
• Product liability or worker-exposure claims

For formaldehyde suppliers, the more relevant competitive threat is process substitution rather than generic competition.

What licensing deals and litigation affect the market?

Publicly disclosed licensing activity is limited at the pharmaceutical-excipient level. Licensing is more likely to occur around:

• Vaccine manufacturing platforms
• Toxoid production
• Decontamination equipment
• Emissions-control systems
• Formaldehyde-free sterilization technologies

There is no widely reported, sector-defining patent litigation campaign comparable with branded-drug litigation involving Paragraph IV filings or biosimilar challenges. Disputes are more likely to involve environmental permits, occupational exposure, product liability, supply contracts or proprietary vaccine processes.

What is the revenue exposure for pharmaceutical suppliers?

Pharmaceutical formaldehyde demand is strategically important but usually not a major revenue contributor for diversified chemical companies. The largest financial exposure is indirect:

• A supplier may lose a high-value vaccine customer after a site or specification change.
• A biologics manufacturer may face production delays after a qualified material becomes unavailable.
• A specialty supplier may earn premium pricing from documentation and supply assurance.
• A chemical producer may face margin compression if industrial demand weakens while pharmaceutical qualification costs remain fixed.

The sector’s financial trajectory is therefore best described as moderate growth with low pharmaceutical volume, high regulatory sensitivity and increasing value concentration in qualified supply.

Key Takeaways

• Formaldehyde is primarily a pharmaceutical process chemical, not a conventional finished-dose excipient.
• Global formaldehyde revenue is approximately $5 billion-$7 billion, while pharmaceutical demand is a small and undisclosed share.
• Vaccine inactivation and toxoid production are the most durable pharmaceutical applications.
• Methanol prices, environmental controls and occupational-safety rules drive supplier margins.
• Formaldehyde has no meaningful Orange Book, Paragraph IV or molecule-level patent-exclusivity position.
• Process patents may protect narrow vaccine, toxoid, sterilization or residual-control methods.
• Substitution risk is highest in facility decontamination and sterilization, not necessarily in validated vaccine processes.
• Regulatory and qualification barriers matter more than intellectual-property barriers.
• Pharmaceutical-grade value growth is likely to exceed volume growth because of documentation, validation and supply-assurance requirements.

FAQs

Is formaldehyde an FDA-approved pharmaceutical excipient?

Formaldehyde is not a routine pharmaceutical excipient for finished oral or injectable products. Its principal regulated pharmaceutical role is as a manufacturing or inactivation agent in selected vaccines and biological products.

Does formaldehyde have an Orange Book patent?

No meaningful Orange Book patent estate exists for formaldehyde as a pharmaceutical product. Orange Book and Paragraph IV frameworks generally do not apply to its commodity chemical supply.

Is formaldehyde used in vaccines?

Yes. It is used in selected vaccine and toxoid manufacturing processes to inactivate pathogens or detoxify bacterial toxins. Residual formaldehyde is controlled under product-specific specifications.

What is the main substitute for formaldehyde in pharmaceutical manufacturing?

The substitute depends on the process. Beta-propiolactone may replace formaldehyde for certain viral inactivation applications, while hydrogen peroxide vapor, chlorine dioxide and peracetic acid compete in decontamination and sterilization.

Is pharmaceutical-grade formaldehyde a high-margin product?

It can command a premium over industrial material because of qualification, documentation and supply-continuity requirements. It remains exposed to commodity economics, hazardous-material controls and environmental compliance costs, so margins are generally less defensible than those of specialized excipients.

References

1. Grand View Research. (2024). Formaldehyde market size, share and trends analysis report. Grand View Research.

2. International Agency for Research on Cancer. (2012). Chemical agents and related occupations: Formaldehyde. In IARC monographs on the evaluation of carcinogenic risks to humans (Vol. 100F). World Health Organization.

3. MarketsandMarkets. (2024). Formaldehyde market by derivative, application and region: Global forecast to 2030. MarketsandMarkets.

4. Occupational Safety and Health Administration. (2024). Formaldehyde: 29 C.F.R. § 1910.1048. U.S. Department of Labor.

5. U.S. Food and Drug Administration. (2024). Inactive ingredient database. U.S. Department of Health and Human Services.